Successful $2.25 Million Capital Raise for Sonnet BioTherapeutics Holding, Inc.
We are delighted to announce that our client, Chardan Capital Markets LLC, has successfully facilitated a capital raise of $2.25 million for Sonnet BioTherapeutics Holdings, Inc. in an overnight registered direct offering and concurrent private placement.
The collaborative efforts of our attorneys and all parties were instrumental in steering this transaction to a successful close. The transaction involved the purchase and sale of an aggregate of 5,000,000 shares of Sonnet's common stock (or common stock equivalents), at a purchase price of $0.45 per share of common stock (or common stock equivalent). It also included issuing warrants for the investor to purchase up to an aggregate of 5,000,000 shares of common stock. The warrants will be exercisable six months from issuance and will expire three and one-half years from the issuance date.
Our role in this transaction underscores our ongoing commitment to our clients and our ability to successfully navigate complex deals. We extend our congratulations to Chardan and Sonnet on this significant achievement. This success is a testament to the hard work and persistence of the teams at both Chardan, Sonnet and our law firm, emphasizing our shared commitment to excellence.